Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies
Executive Summary
Pharmaceutical companies could gain accelerated approval for oncologic agents based solely on pediatric testing of those drugs, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested